A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection

A new vectored vaccine MVA-VLP-SUDV was generated against Sudan ebolavirus (SUDV) combining the advantages of the immunogenicity of a live attenuated vaccine vector (Modified Vaccinia Ankara, MVA) with the authentic conformation of virus-like particles (VLPs). The vaccine expresses minimal component...

Full description

Saved in:
Bibliographic Details
Published in:npj vaccines 2022-07, Vol.7 (1), p.83-83, Article 83
Main Authors: Malherbe, Delphine C., Domi, Arban, Hauser, Mary J., Atyeo, Caroline, Fischinger, Stephanie, Hyde, Matthew A., Williams, Julie M., Alter, Galit, Guirakhoo, Farshad, Bukreyev, Alexander
Format: Article
Language:English
Subjects:
631/250/590/1867
631/326/596/2042
631/326/596/2561
Antibodies
Antigens
Biomedical and Life Sciences
Biomedicine
Disease
Epidemics
Fatalities
Genomes
Glycoproteins
Immunization
Immunogenicity
Immunology
Infectious Diseases
Laboratory animals
Medical Microbiology
Proteins
Public Health
Vaccine
Vaccines
Virology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new vectored vaccine MVA-VLP-SUDV was generated against Sudan ebolavirus (SUDV) combining the advantages of the immunogenicity of a live attenuated vaccine vector (Modified Vaccinia Ankara, MVA) with the authentic conformation of virus-like particles (VLPs). The vaccine expresses minimal components to generate self-assembling VLPs in the vaccinee: the envelope glycoprotein GP and the matrix protein VP40. Guinea pigs vaccinated with one dose of MVA-VLP-SUDV generated SUDV-specific binding and neutralizing antibody responses as well as Fc-mediated protective effects. These responses were boosted by a second vaccine dose. All vaccinated animals which received either one or two vaccine doses were protected from death and disease symptoms following challenge with a lethal dose of SUDV. These data demonstrate single dose protection and potency of the MVA-VLP platform for use in emergency situations to contain outbreaks.
ISSN:2059-0105
2059-0105
DOI:10.1038/s41541-022-00512-x